espite advances in surgical and medical treatments, brain tumors continue to be associated with a dismal prognosis, specifically for glioblastoma multiforme (GBM), for which the short median survival time is only 15 months at best.
ganization responsible for promoting best patient care, developed the Improving Outcomes Guidance for brain and CNS tumors. Its aims are to improve clinical outcomes and the quality of care provided. The Guidance states that neurosurgeons caring for tumor patients should devote at least 50% of their clinical activities to neurooncology. Implementation of this statement would promote subspecialization within surgical neurooncology and restrict the care of brain tumor patients to these surgeons. Although evidence exists for improved outcomes for patients under the care of subspecialists in other areas of neurosurgery, 1, 6, 7 it remains unclear whether the same is true within surgical neurooncology. No recent study has analyzed the potential advantages, and a study published in 1998 showed no benefit, 13 Traditionally, the management of malignant brain tumors has been seen as a core skill, and these cases have therefore been managed by most neurosurgeons. However, specialists would generally make more frequent use of surgical adjuncts including neuronavigation, brain mapping, intraoperative ultrasound, PET, functional MRI, framed and frameless stereotactic biopsies, and many more, which can influence patient outcomes. Some of these adjuncts are widely used by both general and specialist neurosurgeons; however, others might be relevant to specialists only. Furthermore, specialist surgical training allows for a greater experience in neurooncology, which could also contribute to possible differences in outcome. It is believed that specialists are more aggressive at removing tumor mass, but whether doing so is of benefit is still debatable.
17 Despite these differences, fundamental investigations into differences in patient outcome when treatment is provided by a specialist surgical neurooncologist are still lacking, and therefore the advantages of subspecialization in this area remain unclear.
In consideration of this uncertainty, we designed this study to assess the potential differences in morbidity, surgical deaths, and survival times among patients for whom surgery was performed by a specialist surgical neurooncologist (hereafter referred to as a specialist) or a general neurosurgeon (hereafter referred to as a generalist). Because this study was a nonrandomized treatment comparison, we adjusted for case mix to reduce bias and improve the accuracy of our findings.
Methods
An electronic record database was used to identify all patients who had undergone surgery for a malignant supratentorial glioma during 2006-2009 at the Department of Neurosurgery in the Greater Manchester Neurosciences Centre, Salford Royal Hospital, Salford, United Kingdom. The malignant glial tumors included in the analysis were either GBMs or anaplastic astrocytomas (AAs). Patients were divided into 2 groups according to whether their surgery was performed by generalists or specialists. Because cases were treated by the surgeon on call at the time of referral, there was no case selection. Referrals were made from the Greater Manchester and Lancashire catchment area, and the on-call surgeon managed the cases. After patient referral, all cases were discussed at multidisciplinary meetings and otherwise received standard oncological management. Specialists were defined as the 4 core members of the neurooncology multidisciplinary team, all of whom devote at least 50% of their clinical activities to neurooncology.
In accordance with National Institute of Health and Clinical Excellence guidelines, the CNS tumor multidisciplinary team based at the Greater Manchester Neurosciences Centre discusses, without delay, every patient for whom imaging findings suggest a CNS tumor. Neuropathology and neuroradiology services are used and are involved in preoperative and postoperative management decisions and intraoperative diagnoses. Surgical approaches and intraoperative histological evaluations are also discussed. Palliative care specialists and allied health team members are included in the decision-making process.
Demographic information retrieved from the database included patient sex and age, presence and duration of preoperative seizures, and performance status before surgery, according to the WHO scale. Information about the type of surgery (biopsy or debulking) and extent of tumor resection (partial or gross macroscopic, identified by using postoperative imaging and radiology reports) was also collected. The Medical Research Council (MRC) prognostic index was calculated for each patient by using the extent of resection, patient age, history of seizures, and performance status to correct for case mix effects. 19 Survival times and 30-day mortality rates were compared between groups. Differences in duration of inpatient stay and days from referral to multidisciplinary team meetings, from multidisciplinary team meetings to surgery, and from surgery to discharge were also analyzed. Postoperative complications were noted and compared. The benefits of neuronavigation on survival times and on extent of resection were analyzed by comparing surgeries that used neuronavigation with those that did not. Extent of resection was determined by postoperative imaging or radiotherapy planning scans and was interpreted by neuroradiologists. Independent specialist allied health care members assessed patient condition by using morbidity scores including the Waterlow score, 22 which was completed preoperatively, and a patient handling assessment score and a falls risk assessment score, which were completed postoperatively.
The Waterlow score is a validated pressure sore/ulcer risk assessment tool composed of 7 points: build/weight, continence, skin type/visual risk areas, mobility, sex, age, and appetite. The patient handling score is composed of 3 components: patient build/weight for height, comprehension/behavior-language difficulties, and drowsiness and other factors that might affect handling (e.g., pain severity and whether the patient is receiving an intravenous infusion). The falls risk assessment is an 8-point scoring system that takes into account patient sex, age, sensory deficit, fall history, mobility, medical history, medications, and gait.
Patients who needed radiotherapy or chemotherapy were managed at the Christie Cancer Institute and were followed up at various intervals in the neurooncology outpatient clinic and by telephone consultation. The Christie Cancer Institute electronic patient database was used to identify those patients who had received radiotherapy and/or chemotherapy postoperatively, and these parameters were also considered in the analysis. The Christie Hospital is the largest cancer center in Europe; more than 40,000 patients a year receive treatment at this hospital. It was also the first UK center to officially be accredited as a comprehensive cancer center. Patients receive treatment from specialist neurooncology physicians. The standard of treatment at the Christie Hospital is for patients to receive radiotherapy within 1-3 weeks from diagnosis.
Statistical analyses
The Statistical Package for the Social Sciences version 17 (SPSS, Inc.) was used to analyze data. Distribution of data was assessed by skewness, kurtosis, and results of the Kolmogorov-Smirnov test. The log-rank test and a proportional hazards model were used to compare survival times for patients in the specialist and generalist groups. Cox regression was used to assess the effects of covariates (type of surgeon, tumor histology [AA or GBM], postoperative receipt of chemotherapy and/or radiotherapy, type of surgery, extent of tumor removal, and case mix) on survival times. The MRC prognostic index was used as an externally validated method to adjust for differences in case mix. Continuous data, including inpatient stay durations and patient morbidity scores, were assessed by using either the Mann-Whitney U-test or the Student t-test, depending on the distribution of patient stay and morbidity scores. The chi-square or Fisher exact test was used to analyze proportional data.
results
A total of 306 cases of either GBM or AA were discussed. Of these, 171 were excluded from the study: 89 patients received no intervention because of advanced age, extensive comorbidities, extent of disease, and poor performance status; 74 patients had received chemotherapy or radiotherapy; 5 patients died before treatment; and 3 patients refused treatment. The remaining 135 patients underwent surgery for either GBM (n = 116) or AA (n = 19); surgery was performed by specialists for 65 patients (53 GBM and 12 AA) and by generalists for 70 patients (63 GBM and 7 AA) (Fisher exact test, p = 0.122). Specialists performed 51 craniotomies and 14 stereotactic biopsies; generalists conducted 53 craniotomies and 17 stereotactic biopsies. There was no statistical difference between surgeons in the type of operation performed; however, the numbers of macroscopic resections were higher for specialists than for generalists (25 vs 12, respectively; chi-square = 8.147, p = 0.005) (the spread of confounding variables and outcome variables is illustrated in Table 1 ) and were a significant predictor of survival ( Fig. 1 ; Cox regression, p = 0.002).
A crude comparison of survival times demonstrated that median survival time was 290 days (95% CI 217-363 days) for patients who underwent surgery performed by specialists and 196 days (95% CI 144-248 days) for those who underwent surgery performed by generalists (logrank test, p = 0.026). Survival times were longer for patients with AA than for those with GBM (log-rank test, p = 0.001).
Because these results follow a nonrandomized analysis, adjustments for case mix should be considered before interpreting the findings because nonrandomization could add to potential biasing effects. 8 Because prognosis can be influenced by factors including patient age, history of seizures, tumor pathology, and extent of tumor resection, 4, 10, 18, 19 we used the MRC brain tumor prognostic index to form a proportional hazards model for the survival data. The index was a highly significant predictor of survival (Cox regression, p < 0.001); other case mix covariates were assessed for significance.
The effects of case mix were controlled for by using as variables the MRC prognostic index, type of surgeon, extent of tumor resection, tumor pathology, and postoperative treatment with chemotherapy and radiotherapy. Inclusion of these variables demonstrated continued significant improvement in survival times for patients who received treatment from specialists (Cox regression, p = 0.019) (Fig.  2 ). There was a trend toward better 30-day mortality rates for patients who received treatment from specialists; only 4 patients (3%) in the specialist cohort and 10 (7%) in the generalist cohort died. Postoperative chemotherapy and radiotherapy improved survival times (Cox regression, p = 0.001 and p < 0.001, respectively).
Pressure ulcers developed in 2 patients, 1 in each cohort. Significant differences were not found between the 2 cohorts in terms of Waterlow scores (Mann-Whitney U-test, p = 0.179), patient handling assessment scores (chisquare = 2.460, p = 0.117), or falls risk assessment scores (chi-square = 0.499, p = 0.480). Of note, inpatient stays were shorter among patients who underwent surgery performed by specialists than by generalists (Student t-test, p = 0.008) (Fig. 3) .
Neuronavigation was used by specialists in 21 operations and by generalists in 19 operations. An independent analysis of neuronavigation use by specialists and generalists demonstrated no added advantage to the extent of resection. Across both groups, neuronavigation was used in 22 of 105 operations, in which it had no influence on the amount of tumor resected (chi-square = 2.911, p = 0.088). Furthermore, its use did not correlate with survival times (log-rank, p = 0.998).
The length of time from referral to multidisciplinary team discussion and from multidisciplinary team discussion to surgery was also analyzed between groups. No difference was found (Mann-Whitney U-test, p = 0.527 and p = 0.373, respectively).
Discussion
This study provides evidence in support of subspecialization within surgical neurooncology. At the Greater Manchester Neurosciences Centre, overall survival times were longer for patients who underwent surgery performed by specialist surgical neurooncologists than for those who underwent surgery performed by general neurosurgeons. Furthermore, the 30-day mortality rate was lower for the specialist cohort. Although general neurosurgeons undertook a marginally lower operative caseload, this finding probably just reflects the current trend of referring neurooncology cases to specialists. This trend has enabled a comparison of the 2 types of surgeons. Our analysis also demonstrated that specialists would more frequently conduct a macroscopic resection, which correlated with improved survival times. The effect of extent of resection on outcome for patients with malignant supratentorial gliomas remains controversial. It has been documented that the extent of GBM tumor resection and residual tumor volume are highly significant factors affecting survival. 12, 17 Retrospective reports have demonstrated that lobectomies are associated with longer survival times. 9, 11 Furthermore, studies primarily evaluating the benefits of postoperative chemotherapy and radiotherapy contain supporting evidence for prolonged survival after total tumor excision. 5, 21 Evidence also exists for a longer time to tumor progression after macroscopic resections, which could also prolong survival times; 14 imaging studies have confirmed the correlation between lower residual tumor and prolonged survival times. 3, 23 Although there has been some concern that extensive resection can lead to greater neurological deficits and morbidity, these outcomes were not experienced by patients in our study and may even favor a reduction in morbidity.
2 Therefore, therapeutically, our analysis demonstrates a survival advantage after macroscopic tumor resection.
Use of neuronavigation did not statistically influence the extent of tumor resection. This finding might be attributed to the relatively small number of operations in which it was used in our study. Furthermore, the lack of added advantage for completing a macroscopic resection while using neuronavigation might also explain why it did not influence survival times.
The cohort of patients for whom surgery was performed by a specialist also spent significantly less time in hospital after surgery. This finding has many benefits, including reduced cost, less chance of hospital-acquired complications, and possible improvement in patient satisfaction. Morbidity scores did not differ; therefore, the diversity in inpatient stay probably did not result from postoperative recovery but rather might depend on the individual surgeon's decision with regard to time of discharge. Ultimately, if receiving treatment from a specialist neurooncological surgeon provides an outcome advantage, then the reasons are presumably multifactorial. Being a core member of a multidisciplinary neurooncology team facilitates interaction with the whole team caring for patients with brain tumors, including oncologists, radiologists, and specialist nurses. This finding may enable more timely interventions during the many steps in the treatment pathway of patients with CNS tumors.
Our analysis supports the Improving Outcomes Guidance for patients with brain and CNS tumors and provides potential evidence for improved survival times and reduced inpatient stays when surgery is performed by a specialist surgical neurooncologist. These findings may indicate benefits for subspecialization within surgical neurooncology that have yet to be reported. This study had limitations; however, conducting a more scientific analysis of whether patient outcome is better if treatment is given by a neurooncology specialist neurosurgeon is difficult. If patients were asked whether they would agree to random selection as to whether their treatment would be provided by a specialist or generalist, then recruitment would clearly be challenging. Because our study was retrospective and nonrandomized, it was therefore subject to potential selection bias. 15, 16 However, such bias was limited because we corrected for case mix effects by using a multivariate regression model. In addition, the referral process in our center is unlikely to add to selection bias because there was no case selection; cases were treated by the surgeon on call at the time of referral. An analysis of functional outcome, rather than survival time alone, might also be useful as an outcome measure.
Our findings are from a single-center experience, and given further impetus for subspecialization in many centers, conducting subsequent comparative studies might be difficult. Although most centers in the United Kingdom have a similar setup in terms of cases being discussed in neurooncology multidisciplinary team meetings, patient care is increasingly being taken over by specialists, regardless which surgeon was on call. However, it is important that studies in multiple centers are undertaken with adequate powering to confirm these findings so that in the future, patients with this terminal condition receive the best possible care.
conclusions
Our results demonstrate that subspecialization within surgical neurooncology can lead to prolonged patient survival, possibly fewer surgical deaths, and shorter patient hospital stays. Increased amount of tumor resected could contribute to better outcomes. However, our findings remain a single-center experience; to more accurately assess the potential benefits of subspecialization within surgical neurooncology, a multicenter analysis is warranted.
references

